CQ 2-4
33
Ⅰ
乳癌HER2病理診断ガイドライン
検索式・参考にした二次資料
PubMedで,breast cancer, human epidermal growth factor receptor type 2, HER2,
immunohistochemistry, In Situ Hybridization, FISHのキーワードを用いて検索した。
またASCO/CAPガイドライン2013年版を参考とした。ハンドサーチで検索した重要
文献も追加した。
参考文献
1) Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/
College of American Pathologists guideline recommendations for human epidermal
growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25: 118-45.
2) Middleton LP, Price KM, Puig P, et al. Implementation of American Society of Clinical
Oncology/College of American Pathologists HER2 Guideline Recommendations in a ter-
tiary care facility increases HER2 immunohistochemistry and fluorescence in situ hy-
bridization concordance and decreases the number of inconclusive cases. Arch Pathol
Lab Med. 2009;133:775-80.
3) Vergara-Lluri ME, Moatamed NA, Hong E, et al. High concordance between HercepTest
immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after
implementation of American Society of Clinical Oncology/College of American Pathology
2007 guidelines. Mod Pathol. 2012;25:1326-32.
4) Wolf AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College
of American Pathologists Clinical Practice guideline update. J Clin Oncol. 2013;31:3997-
4013.
5) Moelans CB, Reis-Filho JS, van Diest PJ. Implications of rarity of chromosome 17 poly-
somy in breast cancer. Lancet Oncol. 2011;12:1087-9.
6) Vranic S, Teruya B, Repertinger S, et al. Assessment of HER2 gene status in breast car-
cinomas with polysomy of chromosome 17. Cancer. 2011;117:48-53.
7) Tse CH, Hwang HC, Goldstein LC, et al. Determining true HER2 gene status in breast
cancers with polysomy by using alternative chromosome 17 reference genes:implica-
tions for anti—HER2 targeted therapy. J Clin Oncol. 2011;29:4168-74.